10-Q/A: Coeptis Therapeutics Restates Financials for Q2 2023 Due to Accounting Errors

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-Q to restate its financials for the second quarter of 2023 due to errors in accounting for a convertible note and a research agreement.

Summary

• Coeptis Therapeutics Holdings, Inc. has restated its financial statements for the three and six months ended June 30, 2023.
• The restatement was necessary due to errors in accounting for a $350,000 convertible promissory note issued for legal services and a $716,714 corporate research agreement with the University of Pittsburgh.
• The errors impacted the Condensed Consolidated Balance Sheet, specifically Notes payable, current portion, Accrued expenses, and Accumulated deficit, as well as Research and development in the Condensed Consolidated Statement of Operations.
• The company's cash balance was $3,244,812 as of June 30, 2023, compared to $3,791,302 at the end of 2022.
• The net loss for the six months ended June 30, 2023, was $11,160,454, or $0.53 per share, compared to a net loss of $28,982,530, or $2.26 per share, for the same period in 2022.
• The company has an accumulated deficit of $77,250,177 as of June 30, 2023.
• The company issued 2,150,000 shares of common stock, 1,350,000 pre-funded warrants, 3,062,500 Series A Warrants and 3,062,500 Series B Warrants in a public offering for net proceeds of approximately $3.0 million.

Sentiment

Score: 4

Explanation: The document reveals significant financial issues, including a restatement due to accounting errors, a large accumulated deficit, and ongoing losses. While there are some positive developments, such as the recent capital raise, the overall sentiment is negative due to the financial instability and operational challenges.

Positives

• The company completed a public offering in June 2023, raising approximately $3.0 million in net proceeds, which will improve liquidity.
• The company is actively pursuing strategic partnerships and collaborations to develop and commercialize its products and technologies.
• The company has a 50% ownership interest in the CD38-Diagnostic and CD38-GEAR-NK product candidates.

Negatives

• The company had to restate its financial statements due to accounting errors, indicating weaknesses in internal controls.
• The company has a significant accumulated deficit of $77,250,177 as of June 30, 2023.
• The company's net loss for the six months ended June 30, 2023, was $11,160,454.
• The company's cash balance decreased from $3,791,302 at the end of 2022 to $3,244,812 as of June 30, 2023.
• The company has a history of losses and has not yet achieved sustained profitable operations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining sufficient financing or establishing itself as a profitable business.
• The company's internal controls over financial reporting have material weaknesses.
• The company is subject to risks associated with the development and commercialization of pharmaceutical products.
• The company may not be able to successfully develop or commercialize its product candidates.
• The company may not be able to secure additional funding or achieve profitable operations.

Future Outlook

The company expects to generate revenue from product sales and technology licensing, but the timing is uncertain. The company will likely need additional funding to support operations and growth.

Management Comments

• Management determined the previously issued condensed consolidated financial statements do not give effect to the issuance of the note payable nor the corporate research agreement.
• Management believes that additional financing as necessary will result in improved operations and cash flow.
• Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company's target products or technologies.

Industry Context

The company is operating in the competitive pharmaceutical and biotechnology industry, focusing on developing innovative therapies for auto-immune diseases and oncology. The company is pursuing strategic partnerships and collaborations to advance its product pipeline.

Comparison to Industry Standards

• The company's financial performance is weak compared to established pharmaceutical companies, as it is still in the early stages of development and has not yet achieved profitability.
• The company's reliance on external funding is common for early-stage biotech companies, but the need for restatement of financials is a concern.
• The company's focus on CAR-T and NK cell therapies aligns with current trends in the oncology space, but the success of these programs is not guaranteed.
• The company's cash burn rate is high, which is typical for companies in the drug development phase, but the company needs to secure additional funding to continue operations.

Management Changes

Stakeholder Impact

• Shareholders are negatively impacted by the restatement and the company's financial losses.
• Employees may be concerned about the company's financial stability.
• Customers and suppliers may be impacted by the company's ability to continue operations.

Next Steps

• The company will continue to pursue strategic partnerships and collaborations.
• The company will continue to develop its product candidates.
• The company will need to secure additional funding to support its operations and growth.

Key Dates

Keywords

restatement, financial statements, convertible note, research agreement, accounting errors, public offering, warrants, CD38, CAR-T, pharmaceutical, biotechnology